Clinical Trials

Interim data for Pasithea Therapeutics' PAS-004 shows durable activity and superior safety, offering a new strategy for patients who have run out of options.

Interim data shows AC Immune's Alzheimer's candidate is safe, but a pivot to boost its power reveals a high-stakes bet on efficacy over speed.

Novocure's Optune Pax device, using Tumor Treating Fields, gains European approval, offering extended survival and significant pain relief for a deadly disease.

Promising 12-month trial data for SKY-0515 shows it may halt Huntington's, a first for an oral pill. This could disrupt the neuro-market.

Skyhawk Therapeutics' oral drug SKY-0515 not only stabilized but appeared to improve key metrics in Huntington's patients, a profound shift in a field long awaiting a breakthrough.

Positive Phase 3 data for BRUKINSA shows a 43% reduction in cancer progression, heralding a chemotherapy-free future for frontline mantle cell lymphoma.

Cytonics completes a key safety trial for its novel osteoarthritis drug, CYT-108. But the real story is a masterclass in strategic innovation.

GRAIL's revolutionary cancer test failed a key trial, wiping out billions and sparking a fraud lawsuit. A deep dive into the fallout for investors and science.

With Olav Hellebø at the helm, Exonate is advancing a topical eye drop that could end painful eye injections for millions with diabetic retinopathy.

New data on at-home lecanemab injections signals a major shift in Alzheimer's care, promising greater convenience and access for patients and caregivers.

A new chemo-free combo from Genmab and AbbVie shows a 60% reduction in disease progression for a tough-to-treat blood cancer, setting a new standard.

With FDA clearance, Gain Therapeutics' GT-02287, an AI-discovered drug, advances to Phase 2, offering a new hope to modify Parkinson's, not just its symptoms.

FibroBiologics secures $3M with a path to $9M, fueling its promising cell therapy pipeline. But is this a strategic masterstroke or a necessary risk?

With FDA approval for its pivotal TRIUMPH trial, Laplace Interventional is challenging giants in the lucrative tricuspid valve market. A strategic play.

Onkos Surgical hit 500 cases with its NanoCept antibacterial coating. Is this nano-scale tech the key to winning the war on devastating surgical infections?

Evommune halts a key drug trial for chronic hives but leans on a strong cash position and a diversified pipeline to navigate the setback.

A new 'radical collaboration' between top cancer centers is leveraging recent drug breakthroughs to develop combination therapies for pancreatic cancer's deadliest mutation.

CraniUS Therapeutics secures up to $4M in NIH funding for its NeuroPASS device, a refillable implant aiming to revolutionize glioblastoma and CNS treatment.

A new patent for a non-hallucinogenic compound positions Clearmind Medicine to disrupt the multi-billion dollar market for addiction and compulsive disorders.

A landmark real-world study shows an 83.5% response rate for PTSD in patients with comorbid depression, signaling a potential paradigm shift for a notoriously hard-to-treat population.